147 related articles for article (PubMed ID: 18476948)
21. Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital.
Lertkhachonsuk R; Manchana T; Termrungruanglert W; Vasuratna A; Sittisomwong T; Worasethsin P; Sirisabya N; Khemapech N; Tresukosol D
J Med Assoc Thai; 2006 Feb; 89(2):138-44. PubMed ID: 16578998
[TBL] [Abstract][Full Text] [Related]
22. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract][Full Text] [Related]
23. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
Gallion H; Christopherson WA; Coleman RL; DeMars L; Herzog T; Hosford S; Schellhas H; Wells A; Sevin BU
Int J Gynecol Cancer; 2006; 16(1):194-201. PubMed ID: 16445633
[TBL] [Abstract][Full Text] [Related]
24. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.
Ghaemmaghami F; Karimi-Zarchi M; Gilani MM; Mousavi A; Behtash N; Ghasemi M
Asian Pac J Cancer Prev; 2008; 9(3):421-6. PubMed ID: 18990014
[TBL] [Abstract][Full Text] [Related]
25. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
26. Outcome of interval debulking in advanced ovarian cancer patients.
Suprasert P; Tiyanon J; Kietpeerakool C
Asian Pac J Cancer Prev; 2008; 9(3):519-24. PubMed ID: 18990031
[TBL] [Abstract][Full Text] [Related]
27. The Evaluation of Risk Factors Associated With Relapse and Recurrence of Borderline Ovarian Tumors With Long-Term Follow-up.
Sobiczewski P; Kupryjanczyk J; Michalski W; Śpiewankiewicz B
Int J Gynecol Cancer; 2016 Jul; 26(6):1053-61. PubMed ID: 27177283
[TBL] [Abstract][Full Text] [Related]
28. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
29. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
30. Pregnancy outcomes after conservative surgical management of ovarian neoplasms treated at a single institution.
Smaldone GM; Richard SD; Edwards RP
Int J Gynecol Cancer; 2010 Aug; 20(6):926-31. PubMed ID: 20683397
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.
Vasconcelos I; Olschewski J; Braicu I; Sehouli J
Oncologist; 2015 Feb; 20(2):151-8. PubMed ID: 25601963
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort.
Lenhard MS; Mitterer S; Kümper C; Stieber P; Mayr D; Ditsch N; Friese K; Burges A
Eur J Obstet Gynecol Reprod Biol; 2009 Aug; 145(2):189-94. PubMed ID: 19477060
[TBL] [Abstract][Full Text] [Related]
33. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer.
Bryan DN; Radbod R; Berek JS
Int J Gynecol Cancer; 2006; 16(1):125-34. PubMed ID: 16445622
[TBL] [Abstract][Full Text] [Related]
34. Epithelial ovarian tumors of low malignant potential: the role of microinvasion.
Buttin BM; Herzog TJ; Powell MA; Rader JS; Mutch DG
Obstet Gynecol; 2002 Jan; 99(1):11-7. PubMed ID: 11777503
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
36. Malignant transformation of ovarian mature cystic teratoma.
Rim SY; Kim SM; Choi HS
Int J Gynecol Cancer; 2006; 16(1):140-4. PubMed ID: 16445624
[TBL] [Abstract][Full Text] [Related]
37. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
Lorusso D; Ratti M; Ditto A; Raspagliesi F
Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
Leary A; Petrella MC; Pautier P; Duvillard P; Uzan C; Tazi Y; Ledoux F; Gouy S; Morice P; Lhommé C
Gynecol Oncol; 2014 Jan; 132(1):23-7. PubMed ID: 24219980
[TBL] [Abstract][Full Text] [Related]
40. The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer.
Everett EN
Cancer Cytopathol; 2017 Oct; 125(10):743-744. PubMed ID: 28759154
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
